Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - BG Medicine, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R15.htm
EX-32 - EX-32 - BG Medicine, Inc.d398643dex32.htm
EX-10.1 - EX-10.1 - BG Medicine, Inc.d398643dex101.htm
EX-31.2 - EX-31.2 - BG Medicine, Inc.d398643dex312.htm
EX-10.2 - EX-10.2 - BG Medicine, Inc.d398643dex102.htm
10-Q - FORM 10-Q - BG Medicine, Inc.d398643d10q.htm
XML - IDEA: XBRL DOCUMENT - BG Medicine, Inc.R3.htm
EX-31.1 - EX-31.1 - BG Medicine, Inc.d398643dex311.htm
v2.4.0.6
Significant Accounting Policies (Details1) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Summary of computation of basic and diluted net loss per share        
Net loss $ (6,814) $ (4,881) $ (20,870) $ (12,848)
Accretion of redeemable convertible preferred stock       (118)
Net loss attributable to common stockholders $ (6,814) $ (4,881) $ (20,870) $ (12,966)
Weighted average number of shares - basic and diluted 20,320,190 19,344,905 20,118,768 16,925,693
Net loss per share attributable to common stockholders - basic and diluted $ (0.34) $ (0.25) $ (1.04) $ (0.77)